Lepu Medical Received $132 Million Dollars In Series A Financing

Lepu Medical just received around 132 million dollars in Series A financing. This round of financing was led by Shiyu Capital and followed by Sumin Investment and a few other investors. The funds will be used for clinical trials for core projects, the production line builds up and the team builds up.

Lepu Medical was founded in 2018, it mainly focuses on drug development for cancer treatment. The core products of Lepu Medical PD-1, PD-L1, oncolytic virus and multiple ADC products have entered the clinical stage 1 through 3.

At present, Lepu Medical is organizing the company to report on the combined clinical trial of PD-1 monoclonal antibody and oncolytic virus. The main indications are advanced solid tumors and melanoma. PD-L1 type monoclonal antibody has been applied in clinical trials application in June 2018. The indication is for advanced solid tumors.

Shiyu Capital is a professional equity investment and asset management institution, focusing on equity investment in the pharmaceutical and healthcare industry, asset allocation and wealth management.

Sumin Investment is a Chinese state-own investment company.